JP2008534487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534487A5 JP2008534487A5 JP2008502504A JP2008502504A JP2008534487A5 JP 2008534487 A5 JP2008534487 A5 JP 2008534487A5 JP 2008502504 A JP2008502504 A JP 2008502504A JP 2008502504 A JP2008502504 A JP 2008502504A JP 2008534487 A5 JP2008534487 A5 JP 2008534487A5
- Authority
- JP
- Japan
- Prior art keywords
- charged
- apoa
- lipoprotein
- cholesterol
- hdl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66518005P | 2005-03-24 | 2005-03-24 | |
| US60/665,180 | 2005-03-24 | ||
| PCT/IB2006/000635 WO2006100567A1 (en) | 2005-03-24 | 2006-03-23 | Charged lipoprotein complexes and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012063853A Division JP5542166B2 (ja) | 2005-03-24 | 2012-03-21 | 荷電リポタンパク質複合体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534487A JP2008534487A (ja) | 2008-08-28 |
| JP2008534487A5 true JP2008534487A5 (enExample) | 2012-05-17 |
| JP5317691B2 JP5317691B2 (ja) | 2013-10-16 |
Family
ID=36659702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502504A Active JP5317691B2 (ja) | 2005-03-24 | 2006-03-23 | 荷電リポタンパク質複合体およびその使用 |
| JP2012063853A Active JP5542166B2 (ja) | 2005-03-24 | 2012-03-21 | 荷電リポタンパク質複合体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012063853A Active JP5542166B2 (ja) | 2005-03-24 | 2012-03-21 | 荷電リポタンパク質複合体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8206750B2 (enExample) |
| EP (3) | EP2327396A3 (enExample) |
| JP (2) | JP5317691B2 (enExample) |
| KR (4) | KR101769191B1 (enExample) |
| CN (2) | CN103182069B (enExample) |
| AT (1) | ATE547094T1 (enExample) |
| AU (1) | AU2006226045B2 (enExample) |
| BR (1) | BRPI0607728A2 (enExample) |
| CA (1) | CA2602024C (enExample) |
| CY (2) | CY1112783T1 (enExample) |
| DK (2) | DK2289490T3 (enExample) |
| ES (2) | ES2509216T3 (enExample) |
| IL (3) | IL186169A (enExample) |
| MX (1) | MX2007011851A (enExample) |
| NZ (2) | NZ562346A (enExample) |
| PL (2) | PL1871341T3 (enExample) |
| PT (2) | PT1871341E (enExample) |
| SI (2) | SI2289490T1 (enExample) |
| WO (1) | WO2006100567A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006125304A1 (en) * | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Pharmaceutical compositions for treating or preventing coronary artery disease |
| US8163699B2 (en) * | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| WO2010057203A2 (en) | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| DK2396017T3 (en) * | 2009-02-16 | 2015-09-14 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I-mimetika |
| EP2453876A1 (en) | 2009-07-16 | 2012-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hdl comprising a therapeutic agent and use in therapy |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US12419839B2 (en) | 2009-10-09 | 2025-09-23 | Signablok, Inc. | Methods and compositions for targeted delivery of protein fragments |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| EP2517013A4 (en) * | 2009-12-23 | 2013-07-17 | Artery Therapeutics Inc | DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT |
| US20130197226A1 (en) * | 2010-07-28 | 2013-08-01 | Jean-Claude Tardif | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
| EP2611418A2 (en) * | 2010-08-30 | 2013-07-10 | F.Hoffmann-La Roche Ag | Tetranectin-apolipoprotein a-1, lipid particles containing it and its use |
| HUE042314T2 (hu) * | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| AU2015271986B2 (en) * | 2011-02-07 | 2018-02-22 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and manufacturing and uses thereof |
| WO2012135046A1 (en) * | 2011-03-25 | 2012-10-04 | The Trustees Of Columbia University In The City Of New York | Pegylated human hdl particle and process for production thereof |
| BR112013033562A2 (pt) | 2011-08-25 | 2017-02-14 | Hoffmann La Roche | proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas |
| WO2014160237A2 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosing preeclampsia |
| CN105051051B (zh) | 2013-03-15 | 2021-07-16 | 萨瑞斯治疗控股公司 | 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| MX2016014306A (es) | 2014-05-02 | 2017-06-12 | Cerenis Therapeutics Holding Sa | Marcadores para terapia con lipoproteinas de alta densidad (hdl). |
| US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| US20170165200A1 (en) * | 2015-11-20 | 2017-06-15 | University Of North Texas Health Science Center | Composition of lipid-based nanoparticles for small molecules and macromolecules |
| WO2019030574A1 (en) * | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | Cargomers |
| TW201919686A (zh) * | 2017-08-10 | 2019-06-01 | 法商塞勒尼斯醫療控股公司 | 脫輔基子(apomers) |
| CN110151972A (zh) * | 2018-02-11 | 2019-08-23 | 中国中医科学院中医基础理论研究所 | 基于多肽的重组高密度脂蛋白前体及其制备方法与应用 |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| DE202019003092U1 (de) * | 2019-07-24 | 2020-01-17 | Ruth-Maria Korth | Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind |
| CN115666720A (zh) | 2020-04-16 | 2023-01-31 | 阿比奥尼克斯制药公司 | 用于治疗肾病的cer-001疗法 |
| EP4135747A1 (en) | 2020-04-16 | 2023-02-22 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein- based complexes |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| JP2024514154A (ja) | 2021-04-15 | 2024-03-28 | アビオニクス ファーマ エスエー | 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用 |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| EP4504150A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating eye diseases using lipid binding protein-based complexes |
| CN120344255A (zh) | 2022-06-10 | 2025-07-18 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法 |
| EP4536269A2 (en) | 2022-06-10 | 2025-04-16 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein-based complexes |
| AU2024207875A1 (en) | 2023-01-13 | 2025-07-24 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5052123A (enExample) * | 1973-01-18 | 1975-05-09 | ||
| US4466958A (en) | 1981-03-18 | 1984-08-21 | Morrison L M | Food supplement |
| JPS59164553A (ja) * | 1983-03-08 | 1984-09-17 | Fuji Photo Film Co Ltd | カラ−写真感光材料 |
| DE3417696A1 (de) * | 1984-05-12 | 1985-11-14 | Robert Bosch Gmbh, 7000 Stuttgart | Vorrichtung zum volumetrischen abmessen und abfuellen von fluessigkeitsmengen |
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5231090A (en) | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
| US5746223A (en) | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| JP3754072B2 (ja) | 1994-03-22 | 2006-03-08 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | 摂食抑制ペプチド |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| US5948756A (en) | 1995-08-31 | 1999-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Therapeutic lipoprotein compositions |
| IL120005A (en) * | 1997-01-14 | 2000-08-31 | Ramot University Authority Of | Pharmaceutical compositions for the treatment of the eye |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| US6514523B1 (en) | 2000-02-14 | 2003-02-04 | Ottawa Heart Institute Research Corporation | Carrier particles for drug delivery and process for preparation |
| JP2004505035A (ja) | 2000-07-31 | 2004-02-19 | オタワ・ハート・インスティテュート・リサーチ・コーポレーション | 荷電脂質組成物及びその使用方法 |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| CA2457840C (en) | 2001-08-20 | 2011-10-11 | Zlb Bioplasma Ag | Hdl for the treatment of stroke and other ischemic conditions |
| AUPR798901A0 (en) | 2001-09-28 | 2001-10-25 | Medvet Science Pty. Ltd. | Spheroidal hdl particles with a defined phospholipid composition |
| CA2460787A1 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| FR2836043B1 (fr) | 2002-02-15 | 2004-06-04 | Inst Nat Sante Rech Med | Vesicules lipidiques, preparation et utilisations |
| BR0310099A (pt) | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| PL374126A1 (en) * | 2002-05-17 | 2005-10-03 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
| WO2004010939A2 (en) | 2002-07-30 | 2004-02-05 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| US8163699B2 (en) * | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
-
2006
- 2006-03-22 US US11/388,135 patent/US8206750B2/en active Active
- 2006-03-23 ES ES10010660.8T patent/ES2509216T3/es active Active
- 2006-03-23 PL PL06727346T patent/PL1871341T3/pl unknown
- 2006-03-23 CN CN201210518647.4A patent/CN103182069B/zh active Active
- 2006-03-23 NZ NZ562346A patent/NZ562346A/xx unknown
- 2006-03-23 SI SI200631830T patent/SI2289490T1/sl unknown
- 2006-03-23 BR BRPI0607728-5A patent/BRPI0607728A2/pt active Search and Examination
- 2006-03-23 DK DK10010660.8T patent/DK2289490T3/da active
- 2006-03-23 KR KR1020147015584A patent/KR101769191B1/ko active Active
- 2006-03-23 AU AU2006226045A patent/AU2006226045B2/en active Active
- 2006-03-23 MX MX2007011851A patent/MX2007011851A/es active IP Right Grant
- 2006-03-23 EP EP10010652A patent/EP2327396A3/en not_active Withdrawn
- 2006-03-23 AT AT06727346T patent/ATE547094T1/de active
- 2006-03-23 CN CN2006800151378A patent/CN101170994B/zh active Active
- 2006-03-23 WO PCT/IB2006/000635 patent/WO2006100567A1/en not_active Ceased
- 2006-03-23 DK DK06727346.6T patent/DK1871341T3/da active
- 2006-03-23 PT PT06727346T patent/PT1871341E/pt unknown
- 2006-03-23 JP JP2008502504A patent/JP5317691B2/ja active Active
- 2006-03-23 KR KR1020167016313A patent/KR20160077225A/ko not_active Abandoned
- 2006-03-23 CA CA2602024A patent/CA2602024C/en active Active
- 2006-03-23 EP EP06727346A patent/EP1871341B8/en active Active
- 2006-03-23 EP EP10010660.8A patent/EP2289490B1/en active Active
- 2006-03-23 PT PT100106608T patent/PT2289490E/pt unknown
- 2006-03-23 ES ES06727346T patent/ES2382958T3/es active Active
- 2006-03-23 NZ NZ582888A patent/NZ582888A/en unknown
- 2006-03-23 PL PL10010660T patent/PL2289490T3/pl unknown
- 2006-03-23 SI SI200631327T patent/SI1871341T1/sl unknown
- 2006-03-23 KR KR1020187005474A patent/KR20180026548A/ko not_active Ceased
-
2007
- 2007-09-23 IL IL186169A patent/IL186169A/en active IP Right Grant
- 2007-09-24 IL IL186245A patent/IL186245A0/en unknown
- 2007-10-23 KR KR1020077024377A patent/KR101475419B1/ko active Active
-
2012
- 2012-03-21 JP JP2012063853A patent/JP5542166B2/ja active Active
- 2012-05-03 US US13/463,582 patent/US8617615B2/en active Active
- 2012-05-10 IL IL219721A patent/IL219721A/en active IP Right Grant
- 2012-05-15 CY CY20121100451T patent/CY1112783T1/el unknown
-
2013
- 2013-11-20 US US14/085,685 patent/US9567388B2/en active Active
-
2014
- 2014-10-08 CY CY20141100810T patent/CY1115613T1/el unknown
-
2017
- 2017-01-04 US US15/398,219 patent/US11801282B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5317691B2 (ja) | 荷電リポタンパク質複合体およびその使用 | |
| JP2008534487A5 (enExample) | ||
| US7994120B2 (en) | Method of treating dyslipidemic disorder | |
| AU2012202223B2 (en) | Charged lipoprotein complexes and their uses | |
| HK1155389A (en) | Charged lipoprotein complexes and their uses | |
| HK1156840B (en) | Charged lipoprotein complexes and their uses | |
| HK1115823B (en) | Charged lipoprotein complexes and their uses |